4 Analysts Have This To Say About Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) has been evaluated by four analysts in the past three months, with all four maintaining a 'Somewhat Bullish' stance. The average 12-month price target for RARE is now $100.0, down 11.11% from the previous average, with a high estimate of $130.00 and a low of $72.00. Analysts from Cantor Fitzgerald, Wells Fargo, Morgan Stanley, and Piper Sandler have provided ratings and adjusted price targets, reflecting their views on the company's market position and financial performance. Ultragenyx Pharmaceutical is a biopharmaceutical company focusing on rare and ultra-rare diseases, with products like Crysvita, Dojolvi, and Mepsevii. Financially, the company has a high market capitalization and a positive revenue growth rate of 8.1%, but faces challenges with a net margin of -162.82%, ROE of -198.64%, ROA of -12.52%, and a high debt-to-equity ratio of 1.47.
January 19, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical has a consistent 'Somewhat Bullish' rating from analysts, with a reduced average price target of $100. The company's financials show revenue growth but also highlight several challenges such as negative net margin, ROE, ROA, and a high debt ratio.
The unanimous 'Somewhat Bullish' rating by analysts suggests a stable outlook for RARE, but the reduction in the average price target and the company's financial challenges may temper investor enthusiasm in the short term. The high relevance score is due to the direct mention of RARE and detailed analyst ratings. The importance is high as analyst ratings can influence investor perception, but not at the maximum because the ratings are somewhat mixed and not all are upgrades. The confidence level is set at 80, reflecting the clear data provided but acknowledging the inherent unpredictability of market reactions to analyst ratings.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100